Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. [More]
Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis. [More]
UC San Diego-led research team awarded $1.89 million to carry out research on leptospirosis

UC San Diego-led research team awarded $1.89 million to carry out research on leptospirosis

An international research team, headed by Joseph Vinetz, MD, professor of medicine at University of California, San Diego School of Medicine and director of the UC San Diego Center for Tropical Medicine and Travelers Health, has been awarded a 5-year, $1.89 million cooperative agreement to carry out translational research studies of leptospirosis, an infectious and sometimes fatal bacterial disease endemic in much of the world. [More]
Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease. [More]
Oysters play important role in persistence and transmission of norovirus

Oysters play important role in persistence and transmission of norovirus

Oysters not only transmit human norovirus; they also serve as a major reservoir for these pathogens, according to research published August 28 in Applied and Environmental Microbiology, a journal of the American Society for Microbiology. "More than 80 percent of human norovirus genotypes were detected in oyster samples or oyster-related outbreaks," said corresponding author Yongjie Wang, PhD. [More]
Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies. [More]
New study may lead to effective treatment to prevent common chemotherapy side effects in cancer patients

New study may lead to effective treatment to prevent common chemotherapy side effects in cancer patients

Annually, hundreds of thousands of patients battling cancer undergo chemotherapy, which often results in poorly tolerated side effects such as nausea, vomiting, and loss of the desire to eat. [More]
Single dose of oral cholera vaccine could save more lives in crisis situations

Single dose of oral cholera vaccine could save more lives in crisis situations

An oral cholera vaccine that is in short supply could treat more people and save more lives in crisis situations, if one dose were dispensed instead of the recommended two, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
New study reveals that many parents unaware of the dangers of e-cigarettes to children

New study reveals that many parents unaware of the dangers of e-cigarettes to children

As the use of e-cigarettes has risen dramatically in the United States in recent years, so have calls to poison centers about them. Yet many parents who use e-cigarettes - or "vape" - aren't aware of the dangers to children, according to a new study at Washington University School of Medicine in St. Louis. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Shire enters into agreement with Sanquin for CINRYZE

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. [More]
BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis. [More]
Study sheds light on Avoidant/Restrictive Food Intake Disorder

Study sheds light on Avoidant/Restrictive Food Intake Disorder

When most people think of eating disorders, they think of anorexia nervosa and bulimia nervosa. But there's another condition that has nothing to do with concerns over weight, shape or body image, and it has been recognized in the latest edition of the Diagnostic and Statistical Manual of Mental Disorders, which doctors use to diagnose conditions. [More]
Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T. [More]
Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. [More]
Helping relieve headaches in school-aged children

Helping relieve headaches in school-aged children

As the school year approaches and begins, many parents may start to hear their children complain about headaches. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Advertisement
Advertisement